Corneal Endothelial Cell Regeneration via Epigenetic Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating corneal endothelial cell disorders, such as bullous keratopathy, are limited by the inability of human corneal endothelial cells to regenerate and the scarcity of donor corneas, leading to insufficient transplantation options and challenges in maintaining corneal transparency.
Innovation Solution
The use of GPR49/LGR5 as a marker for proliferation and differentiation, combined with R-spondins, particularly R-spondin 1, to suppress differentiation and promote proliferation of corneal endothelial cells in vitro, facilitating the development of therapeutic agents and culture methods for treating and preventing corneal endothelial cell disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If corneal endothelial cells are damaged, then transparency of the cornea is compromised, but the cells have no ability to regenerate themselves
Solution Approach 1:
The patent uses small molecules (such as 5-aza-2'-deoxycytidine and trichostatin A) as intermediaries to inhibit DNA methyltransferase and histone deacetylase, respectively, thereby preventing epigenetic silencing of the OCT4 gene. This mediator approach restores the expression of OCT4 and other stemness markers, enabling corneal endothelial cells to regain proliferative capacity and differentiate into functional cells, thus resolving the contradiction between maintaining corneal transparency and achieving cell regeneration.
2Quantity of substance
If donor corneas are scarce, then transplantation options are limited, but the number of waiting patients is high
Solution Approach 1:
The patent enables corneal endothelial cells to serve themselves by restoring their intrinsic proliferative capacity through epigenetic modulation. By using small molecules to inhibit DNA methyltransferase or histone deacetylase, the method activates endogenous stemness programs in the cells, allowing them to self-renew and self-differentiate into functional corneal endothelial cells without requiring external donor tissues, thus eliminating the dependency on scarce donor corneas.
Solution Approach 2:
The patent applies epigenetic modulators in advance to corneal endothelial cells to reactivate their stemness properties before transplantation or differentiation is needed. This preliminary activation of OCT4 and other stemness markers prepares the cells for subsequent proliferation and functional differentiation, creating a ready supply of functional corneal endothelial cells that can be used immediately for therapeutic purposes.
3Productivity
If corneal endothelial cells are cultured, then they can be expanded, but they differentiate into fibroblast-like cells
Solution Approach 1:
The patent changes the epigenetic parameters of corneal endothelial cells by applying small molecules that inhibit DNA methyltransferase (such as 5-aza-2'-deoxycytidine) or histone deacetylase (such as trichostatin A). These parameter changes in the epigenetic landscape prevent the silencing of the OCT4 gene and other stemness markers, thereby maintaining the cells in an undifferentiated, proliferative state during culture expansion while preserving their identity as corneal endothelial cells rather than allowing differentiation into fibroblast-like cells.
Data Source
Figure 1
Figure 2-1~2-1b
Figure 2-2~2-2e
AI summary
The present invention relates to a differentiation marker and a differentiation controlling technique for an eye cell. More particularly, the present invention has attained an object of providing a differentiation marker for an eye cell among the aforementioned problems, by providing a marker for identifying a cell having a high proliferation ability among corneal endothelial cells and/or the differentiation ability of a corneal endothelial cell, the marker comprising GPR49/LGR5, as well as a detection agent or detection method for identifying a cell having a high proliferation ability among corneal endothelial cells and/or the differentiation ability of a corneal endothelial cell, comprising a substance binding to GPR49/LGR5. In addition, the present invention has attained an object of providing a differentiation controlling technique for an eye cell, by providing an agent for suppressing differentiation and/or promoting proliferation of an eye cell, comprising R-spondins.